KURA Stock Price, Chart, Stats & News
Kura Oncology, Inc. (KURA) does not currently pay a dividend.
KURA chart
Fundamentals
Gross margin | 94.56% |
Operating margin | -449.94% |
Pretax margin | -412.51% |
Net margin | -412.95% |
Effective tax rate | -0.11% |
ROA | -37.74% |
ROE | -102.59% |
D/E | 0.12x |
Interest coverage ratio | -271.34x |
KURA valuation
P/E | – |
P/S | 10.13x |
P/B | 3.91x |
P/CF | -10.64x |
P/FCF | -9.67x |
P/OCF | -10.64x |
PEG | 0.09x |
EV multiple | -2.80x |
About
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Similar securities
Based on sector and market capitalization
